On December 15, 2024, a comprehensive review article written by Boan Biotech titled "Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel the...
Boan Biotech announced that it has signed a licensing agreement for commercializing its self-developed Denosumab Injection (BA6101 and BA1102) in the Brazilian market with a strategic partner.Under th...
Boan Biotech announced that the first patient has been dosed in the Phase 1 clinical trial of BA1302, a novel CD228-directed antibody drug conjugate (ADC), which is the only CD228 ADC undergoing clini...
Asia's premier biomanufacturing summit,BioProcess International Asia 2024(BPI Asia 2024),was held in Koyto, Japan from Oct.21-23. Dr. Changlin Dou, the R&D President and Chief Operating Offi...